On our screens:Stocks with no debtQuality compoundersLow-volatility growth stocksQuality at a reasonable price
Is the price fair?
What STE's price assumes
STERIS plc trades at 27.5× earnings against 30.9× for the median Medical Devices name, cheaper than its own group.
27.5
Trailing P/E · Medical Devices median 30.9 · cheaper than the typical name in its group
- Price / sales
- 3.63
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.8%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +6.2%
Growth the price implies · The price pays for +6.2% free cash flow growth a year for a decade; the business has delivered +35% a year over the last three.
Details›
- Price / book2026-Q1
- 3.00
- EV / EBIT2026-Q1
- 20.8
- EV / sales2026-Q1
- 3.86
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $972M
- Market capitalisation
- $20.2B
- 3-year revenue growth
- +9.4%
- 3-year free cash flow growth
- +35%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $273.67 |
| Its own P/E history, median | $354.57 |
| Its own P/E history, upper quartile | $433.80 |
| 52-week range | $199.40 – $267.17 |
| Today | $218.40 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.